10x Genomics, Inc.
For the period ended Dec 31, 2025. Filed Feb 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 13, 2026
TXG$65.05+9.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except share and per share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Products and services revenue | $596,688 | $610,464 | $618,727 |
| License and royalty revenue | 46,135 | 321 | — |
| Revenue | 642,823 | 610,785 | 618,727 |
| Cost of products and services revenue | 198,942 | 196,303 | 209,414 |
| Gross profit | 443,881 | 414,482 | 409,313 |
| Operating expenses: | |||
| Research and development | 238,632 | 264,698 | 270,332 |
| Selling, general and administrative | 316,134 | 344,343 | 343,330 |
| Gain on settlement | (49,900) | — | — |
| In-process research and development | — | — | 60,980 |
| Total operating expenses | 504,866 | 609,041 | 674,642 |
| Loss from operations | (60,985) | (194,559) | (265,329) |
| Other income (expense): | |||
| Interest income | 20,048 | 18,930 | 16,885 |
| Interest expense | — | (4) | (33) |
| Other income (expense), net | 1,030 | (2,067) | (286) |
| Total other income | 21,078 | 16,859 | 16,566 |
| Loss before provision for income taxes | (39,907) | (177,700) | (248,763) |
| Provision for income taxes | 3,637 | 4,927 | 6,336 |
| Net loss | $(43,544) | $(182,627) | $(255,099) |
| Net loss per share, basic and diluted | $(0.35) | $(1.52) | $(2.18) |
| Weighted-average shares used to compute net loss per share, basic and diluted | 124,749,885 | 120,451,550 | 117,165,036 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.